NASDAQ · DFTX
Definium Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for DFTX: Nov 5, 2026
Definium Therapeutics, Inc. Common Shares is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 7 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.55. The reported EPS for the same quarter last year was $-0.78.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.55 | $-0.45 | $-0.70 | 7 |
| Dec 2026 | $-0.51 | $-0.47 | $-0.55 | 6 |
| Mar 2027 | $-0.50 | $-0.47 | $-0.55 | 3 |
| Jun 2027 | $-0.51 | $-0.46 | $-0.58 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · MarketBeat · Barchart · Zacks- Fintel · Oct 2, 5:47 AM EDTDefinium Therapeutics Consensus Price Target Raised 12.21% to $73.32The average one-year price target for Definium Therapeutics (NASDAQGS:DFTX) (DB:MMQ0) has been revised to $73.32 / share. This is an increase of 12.21% from the prior estimate of $65.34 dated September 11, 2026. These figures represent an aggregate of analyst targets and do not c
- MarketBeat · Sep 24, 2:02 AM EDTDefinium Therapeutics Highlights Phase III DT120 Gains in Anxiety and DepressionDefinium Therapeutics (NASDAQ:DFTX) Chief Medical Officer Dan Karlin said the company’s recent Phase III results for DT120 showed statistically significant improvements in generalized anxiety disorder, or GAD, and major depressive disorder, or MDD, following a single treatment, w
- MarketBeat · Sep 19, 7:02 PM EDTDefinium Therapeutics’ DT120 Hits Phase III Goals in Anxiety StudyDefinium Therapeutics (NASDAQ:DFTX) reported positive top-line results from Panorama, its second Phase III study of DT120 ODT 100 mcgs in generalized anxiety disorder, or GAD. The company said the single-dose treatment met its primary endpoint and all key secondary endpoints, add
- Barchart · Sep 15, 2:17 PM EDTStocks Settle Lower as AI Slowdown Fears Weigh on ChipmakersThe S&P 500 Index ($SPX ) (SPY ) closed down by -0.48% on Monday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.29%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -0.82%. E-mini S&P futures (ESU26 ) fell -0.46%, and September E-mini…
- Zacks · Sep 15, 10:16 AM EDTDefinium Reports Second Phase III Success in Anxiety Disorder ProgramDFTX scores a second phase III GAD win as DT120 ODT delivers significant anxiety improvements, paving the way for FDA talks and a planned 2027 regulatory filing.
- Barchart · Sep 14, 7:07 PM EDTStocks Fall on AI Slowdown Fears and Rising Crude Oil PricesThe S&P 500 Index ($SPX ) (SPY ) is down by -0.65% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down by -0.20%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -1.48%. E-mini S&P futures (ESU26 ) are down -0.58%, and September E-mini…
- Barchart · Sep 14, 6:56 PM EDTStocks Slump on AI Slowdown Fears and Rising Bond Yields and Crude PricesThe S&P 500 Index ($SPX ) (SPY ) is down by -0.83% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down by -0.53%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -1.39%. E-mini S&P futures (ESU26 ) are down -0.80%, and September E-mini…
- RTTNews · Sep 14, 9:17 AM EDTDefinium's DT120 ODT Achieves Significant Anxiety Improvement In Phase 3 Trial; Stock Up(RTTNews) – Definium Therapeutics, Inc. (DFTX) announced positive topline results from Panorama, its second Phase 3 study evaluating DT120 (lysergide) Orally Disintegrating Tablet in adults with generalized anxiety disorder.
- BNK Invest · Aug 20, 3:45 PM EDTNotable Thursday Option Activity: HIMS, DFTX, WULFLooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Hims & Hers Health Inc (Symbol: HIMS), where a total volume of 122,573 contracts has been traded thus far today, a contract volume which is representative of
- RTTNews · Aug 15, 2:59 AM EDTWeekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals(RTTNews) – This week's global biopharma sector roundup captured a mix of regulatory wins, restructuring activities, deals that expanded company pipelines, and clinical trial readouts.
- MarketBeat · Aug 13, 6:04 AM EDTDefinium Therapeutics’ DT120 Meets Phase III Goals in GAD StudyDefinium Therapeutics (NASDAQ:DFTX) reported positive top-line results from Voyage, its Phase III study evaluating a single 100 mcg dose of DT120 ODT for generalized anxiety disorder, or GAD. The company said the trial met its primary endpoint and all key secondary endpoints, sho
- BNK Invest · Aug 12, 3:49 PM EDTNotable Wednesday Option Activity: DFTX, MSGS, TPRLooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Definium Therapeutics Inc (Symbol: DFTX), where a total volume of 14,758 contracts has been traded thus far today, a contract volume which is representative of a
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Definium Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.